CytomX Therapeutics, Inc. (CTMX) intrinsic value & 10-year financials
CytomX Therapeutics, Inc. (CTMX) has a Graham intrinsic value of $12.49 per share. At $2.28 on Oct 17, 2026, the stock trades 82% below that value. Over the last 10 fiscal years revenue grew 21.9% a year to $76.2M, with an average return on invested capital of -9.4%.
- Graham intrinsic value
- $12.49
- Share price (Oct 17, 2026)
- $2.28
- Price vs Graham value
- 82% below
- Market cap
- $314.5M
- Revenue (FY2025)
- $76.2M
- Revenue growth (10-yr CAGR)
- 21.9%
- ROIC (10-yr avg)
- -9.4%
- Free cash flow (FY2025)
- -$75.8M
CTMX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $76.2M | -$17.4M | — | -$75.8M | -29.3% | -85.9% |
| FY2024 | $138.1M | $31.9M | — | -$86.5M | 18.1% | -55.5% |
| FY2023 | $101.2M | -$569.0K | — | -$56.9M | -6.4% | 2.0% |
| FY2022 | $53.2M | -$99.3M | — | -$112.5M | -190.6% | 55.8% |
| FY2021 | $69.6M | -$83.6M | — | -$120.6M | -120.4% | 76.7% |
| FY2020 | $100.4M | -$32.9M | — | $3.0M | -48.4% | 29.3% |
| FY2019 | $57.5M | -$102.2M | — | -$144.0M | -192.9% | 98.2% |
| FY2018 | $59.5M | -$84.6M | — | -$79.3M | -130.9% | -77.6% |
| FY2017 | $71.6M | -$43.1M | — | $168.8M | -64.6% | -61.6% |
| FY2016 | $12.8M | -$58.9M | — | -$4.2M | -463.9% | -75.9% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
CytomX Therapeutics, Inc. is a consistent compounder, expanding top-line revenue at 21.9% annually over the past decade.
CytomX Therapeutics, Inc. has earned high returns on invested capital, averaging 17.2% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
CytomX Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, CytomX Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $12.49 per share.